Hepatic Cirrhosis

29 registered clinical trials studyying Hepatic Cirrhosis — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver NCT07069725	AstraZeneca	Phase 1
Completed	A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosi NCT06750276	AstraZeneca	Phase 2
Not Yet Recruiting	Evaluation of the Efficacy and Safety of Portal Pressure Gradient (PPG) Measurement Guided by Endoscopic Ultra NCT06664307	Hospital Universitario Virgen Macarena	—
Completed	A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV NCT05904470	Atea Pharmaceuticals, Inc.	Phase 2
Completed	A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia NCT06355479	Healthgen Biotechnology Corp.	Phase 3
Unknown	Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers NCT04682847	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	—
Completed	HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC) NCT03804593	Epigenomics, Inc	—
Completed	MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy) NCT03712280	Mallinckrodt	Phase 2
Completed	A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cir NCT03486912	Bristol-Myers Squibb	Phase 2
Completed	A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis NCT03420768	Bristol-Myers Squibb	Phase 2
Completed	A Study of Experimental Medication BMS-986036 Given to Healthy Participants NCT03445208	Bristol-Myers Squibb	Phase 1
Unknown	Human Umbilical Cord-Mesenchymal Stem Cells for Hepatic Cirrhosis NCT02652351	Shenzhen Hornetcorn Bio-technology Company, LTD	Phase 1
Completed	The Treatment of Hepatocirrhosis and Portal Hypertension NCT02778425	Yanjing Gao	N/A
Unknown	Clinical Trial for Evaluation of Treatment With Multiple Infusions of Mononuclear Bone Marrow Cells in Patient NCT02171949	Hospital Sao Rafael	Phase 2
Completed	A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension NCT02230683	Conatus Pharmaceuticals Inc.	Phase 2
Completed	A Study of IDN-6556 in Subjects With Liver Cirrhosis NCT02230670	Conatus Pharmaceuticals Inc.	Phase 2
Completed	A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV NCT02138253	Conatus Pharmaceuticals Inc.	Phase 2
Completed	Effect of Beta-adrenergic Blockers on Cardiac Function, Systemic and Splanchnic Haemodynamic and Kidney Functi NCT02163512	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	—
Completed	Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites NCT01349348	Otsuka Beijing Research Institute	Phase 3
Completed	Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy NCT01135628	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	N/A
Completed	Reproducibility of Child-Turcotte-Pugh (CTP) Rating and NRL972 Pharmacokinetics in Patients With Cirrhosis NCT00896597	Norgine	Phase 1
Completed	Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites NCT01349335	Otsuka Beijing Research Institute	Phase 2
Completed	Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis NCT01359462	Otsuka Beijing Research Institute	Phase 1
Completed	Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of He NCT00698464	Novartis Pharmaceuticals	Phase 1
Completed	Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Dise NCT00794482	Norgine	Phase 3
Completed	Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and Cloxacillin NCT00857480	Norgine	Phase 1
Completed	Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers NCT00856713	Norgine	Phase 1
Completed	Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers NCT00856869	Norgine	Phase 1 / Phase 2
Completed	Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment NCT00006164	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 3